Overview

Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This is a Italian, superiority, open label cluster-randomised, interventional clinical trial aimed at assessing whether the treatment with Hydroxychloroquine can reduce the percentage of symptomatic subjects compared to observation only in household members/contacts of COVID-19 patients (Group 1) and if the treatment with Hydroxychloroquine could be introduced in early phase COVID-19 population (Group 2). The participants will be randomised to receive either: Arm A) hydroxychloroquine vs Arm B) Observation (2:1 randomisation).

Phase:

Phase 2

Details

Lead Sponsor:

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Collaborator:

University of Bologna

Treatments:

Hydroxychloroquine